Shire has reached a long-awaited settlement over patent litigation with Barr Pharmaceuticals over Barr’s attempt to market generic versions of Shire’s attention deficit hyperactivity disorder (ADHD) drug Adderall XR, The Wall Street Journal reported today.
The resolution came as part of a package of deals Shire company signed yesterday, including a research and development deal for women’s health products.
Under the deal, Barr’s Duramed Pharmaceutics unit won’t be permitted to market a generic version of the Adderall XR in the US until April 1, 2009, as it had been seeking to do, with certain exceptions such as another generics company launching a version of the drug. The deal must still clear Federal Trade Commission approval.
Adderall XR is the leading drug in the US for ADHD, with $730 million in global sales in 2005.